Press Releases

Date	Summary	View
Toggle SummaryApr 04, 2019	RedHill Biopharma to Present at Three Conferences in April TEL-AVIV, Israel and RALEIGH, N.C. , April 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that the Company will ...	View HTML PDF Version
Toggle SummaryMar 18, 2019	RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference TEL-AVIV, Israel and RALEIGH, N.C. , March 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...	View HTML PDF Version
Toggle SummaryMar 11, 2019	RedHill Biopharma to Present at the 31st Annual ROTH Conference TEL-AVIV, Israel and RALEIGH, N.C. , March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...	View HTML PDF Version
Toggle SummaryMar 04, 2019	RedHill Biopharma Announces New European and Japanese Patents for Talicia® The European and Japanese patent applications have been accepted and, once granted, are expected to be valid until 2034 U.S. NDA for Talicia ® on track for potential submission in H1/2019 and U.S. commercial launch in Q4/2019 Talicia ® was granted QIDP designation, including eligibility for ...	View HTML PDF Version
Toggle SummaryFeb 26, 2019	RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today reported its full-year 2018 ...	View HTML PDF Version
Toggle SummaryFeb 21, 2019	RedHill Biopharma to Host Full-Year 2018 Financial Results Conference Call on February 26, 2019 TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...	View HTML PDF Version
Toggle SummaryFeb 20, 2019	RedHill Biopharma Strengthens Management Team with Appointment of Rick D. Scruggs as Chief Operating Officer, U.S. Operations TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today ...	View HTML PDF Version
Toggle SummaryFeb 19, 2019	RedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today ...	View HTML PDF Version
Toggle SummaryJan 17, 2019	RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034 NDA submission is expected in H1/2019, with eligibility for 6-month priority review; Subject to FDA approval, U.S. commercial launch with RedHill’s existing sales force is planned for ...	View HTML PDF Version
Toggle SummaryDec 11, 2018	RedHill Biopharma Announces Closing of $20 Million Underwritten Offering TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the ...	View HTML PDF Version

Subscribe to press releases